IBKS No2 SPAC - Asset Resilience Ratio

Latest as of March 2026: 0.26%

IBKS No2 SPAC (204840) has an Asset Resilience Ratio of 0.26% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see 204840 total asset value.

Liquid Assets

₩125.42 Million

≈ $85.00K USD Cash + Short-term Investments

Total Assets

₩48.60 Billion

≈ $32.94 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how IBKS No2 SPAC's Asset Resilience Ratio has changed over time. Read how much debt does IBKS No2 SPAC carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down IBKS No2 SPAC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See 204840 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩125.42 Million	0.26%
Total Liquid Assets	₩125.42 Million	0.26%

Asset Resilience Insights

Limited Liquidity: IBKS No2 SPAC maintains only 0.26% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

IBKS No2 SPAC Industry Peers by Asset Resilience Ratio

Compare IBKS No2 SPAC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd SHG:600276	Drug Manufacturers - Specialty & Generic	0.16%
Sandoz Group AG SW:SDZ	Drug Manufacturers - Specialty & Generic	7.89%
Viatris Inc NASDAQ:VTRS	Drug Manufacturers - Specialty & Generic	1.48%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Walvax BioTech SHE:300142	Drug Manufacturers - Specialty & Generic	2.20%
Shanghai Haoyuan Chemexpress Co. Ltd. A SHG:688131	Drug Manufacturers - Specialty & Generic	1.37%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Cronos Group Inc TO:CRON	Drug Manufacturers - Specialty & Generic	69.94%

Annual Asset Resilience Ratio for IBKS No2 SPAC (2015–2024)

The table below shows the annual Asset Resilience Ratio data for IBKS No2 SPAC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	10.03%	₩4.26 Billion ≈ $2.89 Million	₩42.44 Billion ≈ $28.76 Million	-0.34pp
2023-12-31	10.37%	₩4.14 Billion ≈ $2.80 Million	₩39.87 Billion ≈ $27.02 Million	-0.98pp
2022-12-31	11.36%	₩4.64 Billion ≈ $3.14 Million	₩40.85 Billion ≈ $27.69 Million	-8.61pp
2021-12-31	19.97%	₩6.37 Billion ≈ $4.32 Million	₩31.89 Billion ≈ $21.61 Million	-7.19pp
2020-12-31	27.16%	₩9.49 Billion ≈ $6.43 Million	₩34.94 Billion ≈ $23.68 Million	+24.68pp
2019-12-31	2.48%	₩658.41 Million ≈ $446.19K	₩26.55 Billion ≈ $17.99 Million	-3.10pp
2018-12-31	5.58%	₩1.76 Billion ≈ $1.19 Million	₩31.56 Billion ≈ $21.39 Million	-48.92pp
2017-12-31	54.50%	₩8.19 Billion ≈ $5.55 Million	₩15.02 Billion ≈ $10.18 Million	-4.17pp
2016-12-31	58.67%	₩7.25 Billion ≈ $4.91 Million	₩12.35 Billion ≈ $8.37 Million	+51.14pp
2015-12-31	7.53%	₩667.27 Million ≈ $452.20K	₩8.86 Billion ≈ $6.01 Million	--

pp = percentage points

About IBKS No2 SPAC

KQ:204840 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$48.40 Million

₩71.42 Billion KRW

Market Cap Rank

#22144 Global

#1375 in Korea

Share Price

₩4605.00

Change (1 day)

+0.77%

52-Week Range

₩780.00 - ₩4605.00

All Time High

₩8655.23